患者本人与代理人决策对生命维持治疗及终末期治疗强度的影响
该研究基于韩国国民健康保险服务数据库,纳入2020至2023年间189万042例成人ICU入院,采用高维固定效应模型分析417家医院中POLST签署者身份与终末期治疗强度及住院费用的关联。在90天内死亡患者中,患者本人签署POLST与侵入性终末期治疗几率显著降低相关(OR 0.43,95%CI 0.43-0.54),而代理人签署POLST则使该几率增加一倍以上(OR 2.16,95%CI 1.98-2.35)。即使患者事先有积极预立医疗指示,一旦由代理人签署最终医嘱,治疗强度仍增加(OR 1.69,95%CI 1.51-1.89),呈现「预立医疗指示侵蚀」现象。代理人签署POLST还与每日住院费用显著升高相关(费用比1.04,95%CI 1.02-1.06)。作者认为,POLST限制无益医疗的临床效果根本上取决于签署者身份,早期由患者主导的讨论对确保ICU终末期治疗目标一致至关重要。
要点
- 在90天内死亡患者中,患者本人签署POLST与侵入性终末期治疗几率降低相关(OR 0.43,95%CI 0.43-0.54)。
- 代理人签署POLST与侵入性终末期治疗几率增加一倍以上相关(OR 2.16,95%CI 1.98-2.35)。
- 即使患者有积极预立医疗指示,由代理人签署最终医嘱后治疗强度仍增加(OR 1.69,95%CI 1.51-1.89),即「预立医疗指示侵蚀」。
- 代理人签署POLST与每日住院费用显著升高相关(费用比1.04,95%CI 1.02-1.06)。
- 代理人签署POLST的患病率是患者本人签署的3倍以上。
适用人群与场景
- 2020至2023年间韩国成人ICU入院患者,共189万042例,来自417家医院。
研究设计与关键结果
- 研究类型:全国性基于人群的队列研究,使用韩国国民健康保险服务数据库,纳入189万042例成人ICU入院,覆盖417家医院,采用高维固定效应模型分析。
- 代理人签署POLST(SD-POLST)的患病率是患者本人签署POLST(PD-POLST)的3倍以上。
- 在90天内死亡患者中,PD-POLST与侵入性终末期治疗几率显著降低相关(OR 0.43,95%CI 0.43-0.54);SD-POLST则使该几率增加一倍以上(OR 2.16,95%CI 1.98-2.35)。
- 即使患者有积极预立医疗指示,由代理人签署最终医嘱后治疗强度仍增加(OR 1.69,95%CI 1.51-1.89),即「预立医疗指示侵蚀」现象。
- SD-POLST与每日住院费用显著升高相关(费用比1.04,95%CI 1.02-1.06),对照为无 documentation。
证据类型、等级与局限
- 证据类型:全国性基于人群的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,POLST限制无益医疗的临床效果根本上取决于签署者身份;代理人主导的决策与 paradoxically 更高的治疗强度和费用相关,可能覆盖患者先前意愿。
- 作者认为,早期由患者主导的讨论对确保ICU终末期治疗目标一致至关重要。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Physician orders for life-sustaining treatment (POLST) and advance directives (AD) aim to honor patient autonomy. However, the impact of the signatory's identity-whether the patient or a surrogate-on clinical trajectories in the ICU remains poorly characterized.
OBJECTIVES: The aim was to evaluate the association of signatory identity with terminal care intensity and hospitalization costs among adult patients in the ICU.
METHODS: This nationwide population-based cohort study utilized the South Korean National Health Insurance Service database, including 1 189 042 adult ICU admissions between 2020 and 2023. Statistical analyses employed high-dimensional fixed-effects models to account for institutional variability across 417 hospitals.
RESULTS: Among 1 189 042 patients, surrogate-determined POLST (SD-POLST) was more than 3 times as prevalent as patient-determined POLST (PD-POLST). Among 90-day decedents, PD-POLST was associated with significantly reduced odds of invasive terminal care (OR, 0.43; 95% CI, 0.43-0.54). Conversely, SD-POLST more than doubled the odds (OR, 2.16; 95% CI, 1.98-2.35). Notably, even patients with proactive ADs experienced increased care intensity once a surrogate signed the final order (OR, 1.69; 95% CI, 1.51-1.89), indicating a phenomenon of "AD erosion." SD-POLST also was associated with significantly higher daily hospitalization costs (cost ratio, 1.04; 95% CI, 1.02-1.06) compared with no documentation.
CONCLUSION: The clinical efficacy of POLST in limiting nonbeneficial care depends fundamentally on the signatory. Surrogate-led decisions were associated with paradoxically higher care intensity and costs, potentially overriding prior patient wishes. These findings highlight the critical importance of early, patient-led discussions to ensure goal-concordant end-of-life care in the ICU.
参考来源
- Oh TK, Song IA. Patient versus surrogate decision-making for life sustaining treatment and terminal care intensity. Am J Respir Crit Care Med. 2026. PMID: 42286341. doi:10.1093/ajrccm/aamag276
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。